Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Research

General Health

Professional Services

Genetics

Health Insurance

Public Relations/Investor Relations

Clinical Trials

Science

Biotechnology

Communications

Finance

Health

Other Science

Prasinezumab

More Like This

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to Participate in Upcoming Healthcare Conferences

PR Newswire associated0

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights